{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:51:13Z","timestamp":1790628673250,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pneumonia"],"DOI":"10.1186\/s41479-025-00195-7","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:03:37Z","timestamp":1770249817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Corticosteroids in severe community-acquired pneumonia: friend, foe or both?"],"prefix":"10.1186","volume":"18","author":[{"given":"Federico","family":"Carpenteri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Cilloniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"195_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","volume":"7","author":"A Torres","year":"2021","unstructured":"Torres A, Cilloniz C, Niederman MS, et al. Pneumonia. Nat Rev Dis Primers. 2021;7:25.","journal-title":"Nat Rev Dis Primers"},{"key":"195_CR2","doi-asserted-by":"publisher","first-page":"e065871","DOI":"10.1136\/bmj-2021-065871","volume":"375","author":"C Cill\u00f3niz","year":"2021","unstructured":"Cill\u00f3niz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients. BMJ. 2021;375:e065871.","journal-title":"BMJ"},{"key":"195_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.arbres.2024.12.011","volume":"61","author":"JA Ramirez","year":"2025","unstructured":"Ramirez JA. Cognitive decline in pneumonia: A neglected consequence. Arch Bronconeumol. 2025;61:189\u201390.","journal-title":"Arch Bronconeumol"},{"key":"195_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13054-021-03535-3","volume":"25","author":"A-F Rousseau","year":"2021","unstructured":"Rousseau A-F, Prescott HC, Brett SJ, et al. Long-term outcomes after critical illness: recent insights. Crit Care. 2021;25:108.","journal-title":"Crit Care"},{"key":"195_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12967-020-02646-9","volume":"18","author":"M Blot","year":"2020","unstructured":"Blot M, Bour J-B, Quenot JP, et al. The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. J Translational Med. 2020;18:457.","journal-title":"J Translational Med"},{"key":"195_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41420-023-01766-7","volume":"9","author":"M Cao","year":"2023","unstructured":"Cao M, Wang G, Xie J. Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell Death Discov Nat Publishing Group. 2023;9:465.","journal-title":"Cell Death Discov Nat Publishing Group"},{"key":"195_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","volume":"10","author":"J Nie","year":"2025","unstructured":"Nie J, Zhou L, Tian W, et al. Deep insight into cytokine storm: from pathogenesis to treatment. Sig Transduct Target Ther Nat Publishing Group. 2025;10:112.","journal-title":"Sig Transduct Target Ther Nat Publishing Group"},{"key":"195_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00134-010-2078-z","volume":"37","author":"I Martin-Loeches","year":"2011","unstructured":"Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2011;37:272\u201383.","journal-title":"Intensive Care Med"},{"key":"195_CR9","unstructured":"Jones BE, Ramirez JA, Oren E et al. Diagnosis and management of community-acquired pneumonia. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2025."},{"key":"195_CR10","doi-asserted-by":"publisher","first-page":"106405","DOI":"10.1016\/j.ejim.2025.07.001","volume":"139","author":"G Waterer","year":"2025","unstructured":"Waterer G, Rello J. Redrawing the map for corticosteroids in severe community-acquired pneumonia. Eur J Intern Med. 2025;139:106405.","journal-title":"Eur J Intern Med"},{"key":"195_CR11","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, et al. Derivation, Validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321:2003\u201317.","journal-title":"JAMA"},{"key":"195_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611\u201320.","journal-title":"Lancet Respir Med"},{"key":"195_CR13","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","volume":"5","author":"BP Scicluna","year":"2017","unstructured":"Scicluna BP, van Vught LA, Zwinderman AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017;5:816\u201326.","journal-title":"Lancet Respir Med"},{"key":"195_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13054-020-02866-x","volume":"24","author":"R Wiersema","year":"2020","unstructured":"Wiersema R, Jukarainen S, Vaara ST, et al. Two subphenotypes of septic acute kidney injury are associated with different 90-day mortality and renal recovery. Crit Care. 2020;24:150.","journal-title":"Crit Care"},{"key":"195_CR15","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s00134-024-07593-3","volume":"50","author":"N Bruse","year":"2024","unstructured":"Bruse N, Motos A, van Amstel R, et al. Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients. Intensive Care Med. 2024;50:1884\u201396.","journal-title":"Intensive Care Med"},{"key":"195_CR16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","volume":"9","author":"MF Osuchowski","year":"2021","unstructured":"Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9:622\u201342.","journal-title":"Lancet Respir Med"},{"key":"195_CR17","doi-asserted-by":"publisher","first-page":"e70276","DOI":"10.1002\/jmv.70276","volume":"97","author":"C Garcia-Vidal","year":"2025","unstructured":"Garcia-Vidal C, Teij\u00f3n-Lumbreras C, Aiello TF, et al. COVID-19 patients benefitting from Remdesivir for improved survival: A neural Network-Based approach. J Med Virol. 2025;97:e70276.","journal-title":"J Med Virol"},{"key":"195_CR18","doi-asserted-by":"crossref","unstructured":"Bermejo-Martin JF, Cilloniz C, Mendez R et al. Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. EBioMed. 2017;24:231\u2013236.","DOI":"10.1016\/j.ebiom.2017.09.023"},{"key":"195_CR19","doi-asserted-by":"publisher","first-page":"ofab169","DOI":"10.1093\/ofid\/ofab169","volume":"8","author":"C Cilloniz","year":"2021","unstructured":"Cilloniz C, Peroni HJ, Gabarr\u00fas A, et al. Lymphopenia is associated with poor outcomes of patients with Community-Acquired pneumonia and sepsis. Open Forum Infect Dis. 2021;8:ofab169.","journal-title":"Open Forum Infect Dis"},{"key":"195_CR20","doi-asserted-by":"publisher","first-page":"106131","DOI":"10.1016\/j.jinf.2024.106131","volume":"88","author":"SE Doeleman","year":"2024","unstructured":"Doeleman SE, Reijnders TDY, Joosten SCM, et al. Lymphopenia is associated with broad host response aberrations in community-acquired pneumonia. J Infect. 2024;88:106131.","journal-title":"J Infect"},{"key":"195_CR21","doi-asserted-by":"publisher","unstructured":"Xiao K, Cao Y, Yan P et al. A Large-scale single-cell atlas reveals the peripheral immune panorama of bacterial pneumonia. Am J Respir Crit Care Med [Internet]. 2025. Available from: https:\/\/doi.org\/10.1164\/rccm.202501-0217OC. Cited 8 Sep 2025.","DOI":"10.1164\/rccm.202501-0217OC"},{"key":"195_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2110-5820-1-7","volume":"1","author":"D Annane","year":"2011","unstructured":"Annane D. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann Intensiv Care. 2011;1:7.","journal-title":"Ann Intensiv Care"},{"key":"195_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","volume":"167","author":"JA Kellum","year":"2007","unstructured":"Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch Intern Med. 2007;167:1655\u201363.","journal-title":"Arch Intern Med"},{"key":"195_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1164\/rccm.200712-1777OC","volume":"177","author":"S Yende","year":"2008","unstructured":"Yende S, D\u2019Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177:1242\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"195_CR25","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/S0140-6736(11)60777-0","volume":"377","author":"M Confalonieri","year":"2011","unstructured":"Confalonieri M, Meduri GU. Glucocorticoid treatment in community-acquired pneumonia. Lancet. 2011;377:1982\u20134.","journal-title":"Lancet"},{"key":"195_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.88","volume":"313","author":"A Torres","year":"2015","unstructured":"Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313:677\u201386.","journal-title":"JAMA"},{"key":"195_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","volume":"171","author":"M Confalonieri","year":"2005","unstructured":"Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"195_CR28","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1164\/rccm.200905-0808OC","volume":"181","author":"D Snijders","year":"2010","unstructured":"Snijders D, Daniels JMA, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975\u201382.","journal-title":"Am J Respir Crit Care Med"},{"key":"195_CR29","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(11)60607-7","volume":"377","author":"SCA Meijvis","year":"2011","unstructured":"Meijvis SCA, Hardeman H, Remmelts HHF, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:2023\u201330.","journal-title":"Lancet"},{"key":"195_CR30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","volume":"385","author":"CA Blum","year":"2015","unstructured":"Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511\u20138.","journal-title":"Lancet"},{"key":"195_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-017-1723-0","volume":"21","author":"M Takaki","year":"2017","unstructured":"Takaki M, Ichikado K, Kawamura K, et al. The negative effect of initial high-dose Methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study. Crit Care. 2017;21:135.","journal-title":"Crit Care"},{"key":"195_CR32","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"P-F Dequin","year":"2023","unstructured":"Dequin P-F, Meziani F, Quenot J-P, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388:1931\u201341.","journal-title":"N Engl J Med"},{"key":"195_CR33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00134-022-06684-3","volume":"48","author":"GU Meduri","year":"2022","unstructured":"Meduri GU, Shih M-C, Bridges L, et al. Low-dose Methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022;48:1009\u201323.","journal-title":"Intensive Care Med"},{"key":"195_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00134-025-07861-w","volume":"51","author":"REMAP-CAP Investigators","year":"2025","unstructured":"Investigators REMAP-CAP, Angus DC. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia: the REMAP-CAP corticosteroid domain randomized clinical trial. Intensive Care Med. 2025;51:665\u201380.","journal-title":"Intensive Care Med"},{"key":"195_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S2213-2600(23)00430-7","volume":"12","author":"N Heming","year":"2024","unstructured":"Heming N, Renault A, Kuperminc E, et al. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med. 2024;12:366\u201374.","journal-title":"Lancet Respir Med"},{"key":"195_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12890-025-03679-w","volume":"25","author":"L Zhu","year":"2025","unstructured":"Zhu L, Zeng J, Li H, et al. Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis. BMC Pulm Med. 2025;25:210.","journal-title":"BMC Pulm Med"},{"key":"195_CR37","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1007\/s11606-023-08203-6","volume":"38","author":"T Pitre","year":"2023","unstructured":"Pitre T, Abdali D, Chaudhuri D, et al. Corticosteroids in Community-Acquired bacterial pneumonia: a systematic Review, pairwise and Dose-Response Meta-Analysis. J Gen Intern Med. 2023;38:2593\u2013606.","journal-title":"J Gen Intern Med"},{"key":"195_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00134-025-07912-2","volume":"51","author":"T Pitre","year":"2025","unstructured":"Pitre T, Pauley E, Chaudhuri D, et al. Corticosteroids for adult patients hospitalised with non-viral community-acquired pneumonia: a systematic review and meta-analysis. Intensive Care Med. 2025;51:917\u201329.","journal-title":"Intensive Care Med"},{"key":"195_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-2600(24)00405-3","volume":"13","author":"JM Smit","year":"2025","unstructured":"Smit JM, Van Der Zee PA, Stoof SCM, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. Lancet Respir Med. 2025;13:221\u201333.","journal-title":"Lancet Respir Med"},{"key":"195_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/cid\/cix801","volume":"66","author":"M Briel","year":"2018","unstructured":"Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with Community-Acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis. 2018;66:346\u201354.","journal-title":"Clin Infect Dis"},{"key":"195_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1378\/chest.15-1733","volume":"149","author":"Y-D Wan","year":"2016","unstructured":"Wan Y-D, Sun T-W, Liu Z-Q, et al. Efficacy and safety of corticosteroids for Community-Acquired pneumonia: A systematic review and Meta-Analysis. Chest. 2016;149:209\u201319.","journal-title":"Chest"},{"key":"195_CR42","doi-asserted-by":"publisher","first-page":"e0165942","DOI":"10.1371\/journal.pone.0165942","volume":"11","author":"J Bi","year":"2016","unstructured":"Bi J, Yang J, Wang Y, et al. Efficacy and safety of adjunctive corticosteroids therapy for severe Community-Acquired pneumonia in adults: an updated systematic review and Meta-Analysis. PLoS ONE. 2016;11:e0165942.","journal-title":"PLoS ONE"},{"key":"195_CR43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/M15-0715","volume":"163","author":"RAC Siemieniuk","year":"2015","unstructured":"Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with Community-Acquired pneumonia: A systematic review and Meta-analysis. Ann Intern Med. 2015;163:519\u201328.","journal-title":"Ann Intern Med"},{"key":"195_CR44","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00134-015-4095-4","volume":"42","author":"GU Meduri","year":"2016","unstructured":"Meduri GU, Bridges L, Shih M-C, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients\u2019 data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42:829\u201340.","journal-title":"Intensive Care Med"},{"key":"195_CR45","doi-asserted-by":"publisher","first-page":"2200735","DOI":"10.1183\/13993003.00735-2022","volume":"61","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, Torres A, Nagavci B, et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. 2023;61:2200735.","journal-title":"Eur Respir J"},{"key":"195_CR46","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1097\/CCM.0000000000006172","volume":"52","author":"D Chaudhuri","year":"2024","unstructured":"Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 focused update: guidelines on use of corticosteroids in Sepsis, acute respiratory distress Syndrome, and Community-Acquired pneumonia. Crit Care Med. 2024;52:e219\u201333.","journal-title":"Crit Care Med"},{"key":"195_CR47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12890-023-02794-w","volume":"23","author":"CA Blum","year":"2023","unstructured":"Blum CA, Roethlisberger EA, Cesana-Nigro N, et al. Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial. BMC Pulm Med. 2023;23:500.","journal-title":"BMC Pulm Med"},{"key":"195_CR48","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.chest.2016.11.036","volume":"151","author":"PE Marik","year":"2017","unstructured":"Marik PE, Khangoora V, Rivera R, et al. Vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151:1229\u201338.","journal-title":"Chest"},{"key":"195_CR49","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00134-025-07947-5","volume":"51","author":"J Helms","year":"2025","unstructured":"Helms J, Ferrer R, Torres A. Corticosteroids in non-viral community-acquired pneumonia: edging closer to yes. Intensive Care Med. 2025;51:1139\u201341.","journal-title":"Intensive Care Med"},{"key":"195_CR50","doi-asserted-by":"crossref","unstructured":"Papadopoulou E, Safar SB, Khalil A et al. Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis. Eur Res Rev [Internet]. 2024;33. Available from: https:\/\/publications.ersnet.org\/content\/errev\/33\/171\/230151. Cited 8 Sep 2025.","DOI":"10.1183\/16000617.0151-2023"},{"key":"195_CR51","doi-asserted-by":"crossref","unstructured":"Niederman MS, Pneumonia Complicating COPD. Are corticosteroids a help or a hindrance? Chronic Obstr Pulm Dis 5: 1\u20134.","DOI":"10.15326\/jcopdf.5.1.2018.0162"}],"container-title":["Pneumonia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-025-00195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41479-025-00195-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-025-00195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:03:38Z","timestamp":1770249818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41479-025-00195-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["195"],"URL":"https:\/\/doi.org\/10.1186\/s41479-025-00195-7","relation":{},"ISSN":["2200-6133"],"issn-type":[{"value":"2200-6133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to publish declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}